Graft Versus Host Diseases Market
Number of pages: 100 | Report Format: PDF | Published date: 02 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 3.42 billion |
|
Revenue forecast in 2031 |
US$ 12.67 billion |
|
Growth Rate |
CAGR of 14% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Treatment Type, Disease Type and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global graft versus host diseases market was valued at US$ 3.42 billion in 2021 and is expected to register a revenue CAGR of 14% to reach US$ 12.67 billion by 2031.
Market Fundamental
Graft versus host disease (GvHD) is a disease that develops following an allogeneic bone marrow or stem cell transplant. Graft versus host disease (GvHD) is a potentially fatal condition following a transplant with a genetically distinct individual. GvHD is divided into two types: acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) (cGvHD). Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation. It is the subject of much ongoing research. Despite tremendous advances in understanding the pathogenesis, diagnosis, and risk factors for both acute and chronic forms of the illness, a comprehensive therapy approach remains inadequate. Corticosteroid therapy effectively treats acute and chronic forms of the condition. However, the most effective treatment for steroid-refractory illness is still debatable.
[658568]
Market Dynamics
The rising prevalence of graft versus host disease (GvHD), caused mostly by an increase in the number of allogeneic transplants, is creating a large patient pool in need of therapy. This is one of the primary elements driving the expansion of the worldwide graft versus host disease (GvHD) treatment market. The World Health Organization (WHO) reports that the prevalence of GvHD is rising due to an increase in the bone marrow and organ transplants. The increasing number of transplants is expected to drive market growth. In addition, an increasing number of product approvals for the treatment of graft versus host disease (GvHD) and an increase in illness detection rate are some of the factors driving the global graft versus host disease (GvHD) treatment market. According to The Leukemia & Lymphoma Society (LLS), chronic graft versus host disease (GvHD) can occur in 30-70% of allogeneic transplant recipients.
Furthermore, the growing number of clinical trials for GvHD is expected to drive market growth. For example, a study conducted by the National Institute of Health (NIH) in the United States discovered that a combination of ruxolitinib and sirolimus was effective in treating GvHD. The researchers concluded that combination therapy was safe and effective in treating GvHD.
Market Ecosystem
The global graft versus host disease market has been analyzed from three perspectives: Treatment Type, Disease Type and Region.
Graft Versus Host Diseases by Treatment Type
[4654646]
Based on treatment type, the global graft versus host disease market has been segmented into immunosuppressants, corticosteroids, mTOR inhibitors, tyrosine kinase inhibitors, monoclonal antibodies, and others.
The immunosuppressants segment currently dominates the global market. This trend will continue in the future due to an increase in the number of targeted drug therapies for treating acute and chronic GVHD with immunosuppressants. Moreover, the increase in the number of populations suffering from conditions such as cardiovascular disease, cancer, and nephrological disorders, also contributes to the growth of the graft versus host disease market size. During the projection period, corticosteroids are expected to be the fastest-increasing segment because steroids are normally produced in modest amounts in the body, thereby demanding external administration. They aid in regulating several activities, including the immune system, inflammation reduction, and blood pressure control.
Graft Versus Host Diseases by Disease Type
Based on disease types, the global graft versus host disease market has been segmented into acute GVHD, chronic GVHD, and prophylaxis GVHD.
The acute GVHD segment contributed the most revenue to the market, owing to an increase in the geriatric population, an increase in the prevalence of graft versus host disease, and an increase in the number of allogeneic transplants. Chronic GVHD is predicted to be the fastest-growing segment during the market forecast period.
Graft Versus Host Diseases by Region
Based on region, the global graft versus host disease market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global graft versus host disease market in 2022. The high prevalence of graft versus host disease (GvHD) due to growing transplantation procedures in the region is expected to boost the expansion of the GvHD treatment market. According to a study released in 2018 by the National Center of Biotechnology Information, 30% to 50% of hematopoietic stem cell transplant (HSCT) recipients have acute GVHD. This translates to 5,500 patients per year developing acute graft versus host disease. Around 50% of individuals with acute graft versus host illness will eventually develop chronic graft versus host disease.
GvHD is a major cause of morbidity and mortality in stem cell transplant patients, and its prevalence is rising in the Asia Pacific region. During the forecast period, the Asia Pacific graft versus host diseases market is expected to grow at a rapid pace. The market is expanding due to an increase in the number of stem cell transplants, increased awareness of stem cell transplants, and increased government initiatives to support stem cell research. Furthermore, the rising prevalence of cancers such as leukemia, lymphoma, and multiple myeloma is expected to fuel the growth of the Asia Pacific graft versus host diseases market.
The Asia Pacific market for graft versus host diseases is highly competitive, with several major players. F. Hoffmann-La Roche Ltd., Celgene Corporation, Bristol-Myers Squibb, Novartis AG, and Pfizer Inc. are some of the key players in this market. Key players are focusing on strategic initiatives such as collaborations, product launches, mergers and acquisitions, and partnerships to gain a strong foothold in the Asia Pacific graft versus host diseases market. Celgene Corporation, for example, announced a collaboration with Juno Therapeutics in December 2017 to develop and commercialize JCAR017, an investigational chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Competitive Landscape
Some of the prominent market players in the global graft versus host diseases market include
The global graft versus host diseases (GvHD) market is highly competitive and is dominated by a few key players. These players are focusing on developing innovative solutions for the treatment of GvHD. In addition, these companies are also focusing on collaborations and partnerships to strengthen their position in the market. For instance, in 2020, Gilead Sciences and Kite Pharma announced a collaboration to develop a novel therapy for GvHD. The collaboration is expected to reduce the cost of GvHD treatment. Moreover, these companies are also focusing on expanding their product portfolios to gain a competitive advantage in the market. For instance, in 2020, Kite Pharma announced the launch of Yescarta, a novel therapy for GvHD. The launch of the product is expected to strengthen Kite Pharma’s position in the market. In addition to the key players, there are also a number of small and medium-sized players in the market. These players are focusing on developing innovative solutions for the treatment of GvHD. For instance, in 2020, Immunovant Inc. announced the launch of IMVT-1401, a novel therapy for GvHD. The launch of the product is expected to create opportunities for the company.
Strategic Developments
The Asia Pacific is the key growth region in the global graft versus host market
The increasing rate of bone marrow or hematopoietic stem cell treatment and increasing number of pipeline drugs.
The graft versus host diseases market is expected to clock US$ ~ 11.12 billion by 2030.
The global graft versus host diseases market is expected to witness a CAGR of 14% during the forecast period.
Some of the prominent market player in the global graft versus host disease market include Incyte Corporation, Janssen Pharmaceuticals Inc., Abbvie Inc. and others.
*Insights on financial performance is subject to availability of information in public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst